Chronic lymphocytic leukaemia trials in Australia

In Australia 29 Also abroad 308

29 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Where
Adelaide, Box Hill, Melbourne
Age
18 years and over
People
735 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00
Phase 1Taking people
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Where
East Melbourne, Melbourne, Woolloongabba
Age
18 years and over
People
332 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05091424
Phase 2Taking people
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Where
Adelaide, Bankstown, Box Hill, Coffs Harbour, Hobart, Kurralta Park, Traralgon, Waratah, West Perth, Woolloongabba
Age
18 years and over
People
249 worldwide
Run by
Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Macquarie University, Melbourne, Nedlands, Randwick
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 4Taking people
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Where
Melbourne
Age
18 years and over
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07218341
Phase 1/2Taking people
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Where
Heidelberg, Melbourne, Nedlands
Age
18 years and over
People
408 worldwide
Run by
AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00
Phase 2Taking people
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Where
Box Hill, Nedlands, Sydney
Age
18 years and over
People
490 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00
Phase 1/2Taking people
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Where
Adelaide, Blacktown, Cooloongup, Malvern, Melbourne, Nedlands
Age
18 years and over
People
258 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06697184 · EU 2024-518829-15-00
Phase 3Taking people
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Where
Birtinya, Blacktown, Clayton, Cooloongup, Fitzroy, Kogarah, Lismore, Melbourne, North Ryde, St Leonards, West Perth, Woolloongabba
Age
18 years and over
People
630 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00
Phase 1Taking people
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Where
Fitzroy, Saint Leonards
Age
18 years and over
People
106 worldwide
Run by
Umoja Biopharma
See details and how to joinNCT06528301
Phase 3Taking people
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Where
St Leonards
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01
Phase 3Taking people
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Where
Adelaide, Fitzroy, Heidelberg, Nedlands, Perth, Rockingham
Age
18 years to 18 years
People
420 worldwide
Run by
AstraZeneca
See details and how to joinNCT07509151
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Concord, Fitzroy, Heidelberg, Melbourne, Nedlands, Waratah, West Perth, Woolloongabba
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 1/2Taking people
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
Where
Melbourne
Age
18 years and over
People
112 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT05791409 · EU 2022-500305-40-00
Phase 1/2Taking people
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Where
Melbourne, Nedlands
Age
18 years and over
People
174 worldwide
Run by
AstraZeneca
See details and how to joinNCT06542250
Phase 3Taking people
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Where
Bedford PK, Concord, Gosford, Melbourne, Port Macquarie, Randwick, Toowoomba, West Perth
Age
18 years and over
People
250 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06846671 · EU 2024-518893-15-00
Phase 3Taking people
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Where
Bedford PK, Benowa, Birtinya, Concord, Fitzroy, Frankston, Heidelberg, Kogarah, Malvern, Melbourne, Nedlands, Tugun, Westmead
Age
18 years and over
People
500 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00
Phase 3Taking people
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Where
Blacktown, Clayton, Concord, Heidelberg, Malvern, Melbourne, St Leonards, Woolloongabba
Age
18 years and over
People
500 worldwide
Run by
BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00
Phase 1Taking people
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Where
Adelaide, Camperdown, Fitzroy, Geelong, Liverpool
Age
18 years and over
People
135 worldwide
Run by
Imugene Limited
See details and how to joinNCT03666000
Phase 2Taking people
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
Where
Melbourne
Age
18 years and over
People
40
Run by
Peter MacCallum Cancer Centre, Australia
See details and how to joinNCT06812715
Phase 3Taking people
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Where
Nedlands, St Albans, West Perth
Age
18 years and over
People
737 worldwide
Run by
Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00
Phase 3Taking people
Global Trial in APG2575 for Patients With CLL/SLL
Where
Gosford, Perth, Westmead
Age
18 years to 99 years
People
400 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00
Phase 3Taking people
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Where
Fitzroy, Perth, Townsville, Waratah
Age
18 years and over
People
170 worldwide
Run by
AbbVie
See details and how to joinNCT06428019 · EU 2024-512147-23-00
Phase 4Taking people
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Where
Adelaide, Melbourne, Victoria
Age
18 years and over
People
787 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06876649
Phase 4Taking people
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Where
Adelaide, Melbourne, Victoria
Age
18 years and over
People
279 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06876662